Roflumilast therapy in COPD − Update and Trials
Loading...
Date
2015-07
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Ibn Sina Academy of Medieval Medicine & Sciences
Abstract
Chronic Obstructive Pulmonary Disease (COPD) represents an important public health challenge that is both preventable and treatable. Pharmacological treatment regimen for COPD needs to be patient specific. Hence management of COPD should be based on strategy considering both disease impact and future risk of disease progression ( especially of exacerbation ). Risk of exacerbations significantly increases in GOLD 3 and GOLD 4 COPD. Exacerbations increase the decline in lung function , deteorriation in health status and risk of death.
Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor. It reduces risk of moderate to severe exacerbations in patients of GOLD 3 & GOLD 4 COPD. It has no direct bronchodilator activity, although it has been shown to improve FEV1 in patients treated with inhaled long-acting bronchodilator. Adverse effects may occur early during the treatment but these are reversible and diminish overtime with continued treatment .
Description
Keywords
Anti-inflammatory, Chronic obstructive pulmonary disease, Phosphodiesterase 4 inhibitor, Roflumilast
Citation
Giri Om Prakash, Giri Vishal Prakash. Roflumilast therapy in COPD − Update and Trials. International Archives of BioMedical and Clinical Research. 2015 Jul-Sep; 1(1): 31-36